BOSTON, Oct. 25, 2016 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in digital health and mobile health solutions and the developer of the Dario™ Blood Glucose Monitoring System, an all-in-one diabetes meter, today announced continued adoption for its revolutionary mobile app-based and minimally invasive smart diabetes management solution. In just six months since its U.S. launch, Dario is demonstrating positive trends in terms of meters purchased in the U.S.
- More than 10,000 Dario all-in-one smart glucose meter devices were purchased by U.S. customers by Sep. 30, 2016, of which more than 5,500 were purchased in the third quarter, doubling its market presence by the end of the third quarter.
- At September end, the Company had more than 10,900 users registered on its servers, more than doubling its June 30 registered users, of these users more than 10,000 have ordered strips.
- About 65% of the total strips sold since launch, were purchased by users under our subscription plan contributing to the recurring revenue model.
"We are very pleased with the initial six months since our March 2016 soft launch in the U.S.," said Erez Raphael, DarioHealth's Chairman and Chief Executive Officer. "The favorable moves in our conversion and usage trends demonstrate the positive engagement we are achieving with Dario users. Our digital marketing team continues to refine our messaging and delivery with a goal of making our customer acquisition as efficient as possible. Our user engagement team continues to make strides in successfully converting a higher percentage of users to recurring revenue users for our strips, we anticipates consistent quarter over quarter revenue growth for foreseeable future."
About DarioHealth Corp.
DarioHealth is a leader in digital health self-management solutions. DarioHealth delivers the ability to combine and analyze consumer health data to personalize treatment and advance medical knowledge. Dario's™ smart diabetes management solution is a platform for diabetes management that combines the Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter, native smart phone app, website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems. Having recently launched in the largest market in the world for glucose monitoring, U.S. sales are expected to have a significant impact on revenues and gross margins. With marketing clearance in Europe and the U.S., the Dario iOS mobile app recently launched with reimbursement in the United Kingdom, Australia, Israel, Italy, and Canada, and has also launched in New Zealand, Netherlands, Italy, and Belgium. For more information, visit http://mydario.investorroom.com/
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, when the Company describes its growth potential, describes the expected benefits of direct to consumer sales in Australia, and says that U.S. sales are expected to have a significant impact on the Company's revenues and gross margins, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate and Media Contact
DarioHealth Investor Relations Contact
Rob Fink / Brett Maas
+1-646-415-8972 / +1-646-536-7331
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dariohealth-reports-successful-traction-for-dario-300350573.html
SOURCE DarioHealth Corp.